AstraZeneca and Moderna Present Results of AZD8601 in P-IIa EPICCURE Trial for the Treatment of Heart Failure at AHA 2021
Shots:
- The P-IIa EPICCURE trial evaluates safety, tolerability & exploratory efficacy of epicardial inj. of AZD8601 vs PBO in 11 patients (7 were treated with AZD8601 & 4 received PBO inj.) with stable CAD & decreased LVEF who undergoes CABG surgery. The therapy is being co-developed with Moderna
- The study met its 1EPs i.e., numerical trends were identified in 3 exploratory efficacy EPs over PBO, including an increase in LVEF & functional PROs, 7 patients treated with AZD8601 had NT-proBNP
- AZD8601 is a novel mRNA-based therapy that encodes for VEGF-A. AstraZeneca has signed an exclusive agreement with Moderna to discover & commercialize mRNA therapeutics for multiple diseases
Ref: AstraZeneca | Image: Mint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com